Latest Content

University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.

A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

Antineoplastics were the most frequently implicated drug class in review

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her AOA Optometry's Meeting 2026 session.

Erin Rueff, OD, PhD, FAAO, provides tips to fellow clinicians on how to keep these patients comfortable in their lenses.

Healome’s proprietary eye drop-matrix behaves like a liquid when it is dropped on the eye, and then restructures on the ocular surface to form a clear, lubricating, protective matrix that can deliver a broad range of drugs.

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

As of July 13, 2026, a meeting date has not been set.